Page last updated: 2024-11-05

indolebutyric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

indolebutyric acid: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

indole-3-butyric acid : A indol-3-yl carboxylic acid that is butanoic acid carrying a 1H-indol-3-yl substituent at position 1. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8617
CHEMBL ID582878
CHEBI ID33070
SCHEMBL ID35884
SCHEMBL ID1087345
MeSH IDM0063266

Synonyms (169)

Synonym
4-(1h-indol-3-yl)-butyric acid
BB 0242435
jiffy grow
3-indolylbutyric acid
butyric acid, 4-(indolyl)-
indolyl-3-butyric acid
.gamma.-(3-indolyl)butyric acid
.gamma.-(indol-3-yl)butyric acid
.gamma.-(indole-3)-butyric acid
indol-3,4'-yl butyric acid
3-indolyl-.gamma.-butyric acid
seradix
4-(indol-3-yl)butyric acid
wln: t56 bmj d3vq
hormodin
indolbutyric acid
1h-indole-3-butyric acid
3-indolebutyric acid ,
.gamma.-indolebutyric acid
indole-3-butanoic acid
.gamma.-indole-3-butyric acid
.beta.-iba
1h-indole-3-butanoic acid
nsc-3130
.beta.-indolebutyric acid
CHEBI:33070 ,
ENAMINE_005659
einecs 205-101-5
kyselina 4-indol-3-ylmaselina [czech]
brn 0171120
4-indol-3-ylbutyric acid [bsi:iso]
nsc 3130
CBKINASE1_012484
CBDIVE_001082
OPREA1_136608
4-(1h-indol-3-yl)butanoic acid
CBKINASE1_000084
OPREA1_093618
ccris 1020
4-(1h-indol-3-yl)butyric acid
indole-3-butyric acid (8ci)
4-(3-indolyl)butyric acid
gamma-(indole-3)-butyric acid
seradix b 2
seradix 3
1h-indole-3-butanoic acid (9ci)
hsdb 7214
beta-indolebutyric acid
rhizopon aa
[3-(3-indolyl)propyl]carboxylic acid
seradix 2
4-(3-indolyl)butanoic acid
hormex
seradix b 3
oxyberon
ai3-17434
3-indolyl-gamma-butyric acid
epa pesticide chemical code 046701
caswell no. 499
indole-3-butyric acid
133-32-4
IBA ,
indolebutyric acid
indole-3-butyric acid, plant cell culture tested, bioreagent
DB02740
3IB ,
NCGC00164296-01
IDI1_007894
I-2005
I-2000
I-2010
STK246981
indole-3-butyric acid, >=99.0% (t)
67085FE2-19DF-4524-B354-17BD9781B318
AC-2855
AKOS000273851
bdbm50129081
BRD-K43187796-237-01-5
HMS1410B05
4-indol-3-ylbutyric acid
CHEMBL582878
FT-0691186
I0026
3-indolebutyrate
BBL000073
tox21_301287
dtxsid8032623 ,
cas-133-32-4
NCGC00257530-01
dtxcid6012623
BCP9000128
CCG-110315
4-indol-3-ylbutanoic acid
F0919-1266
5-22-03-00140 (beilstein handbook reference)
kyselina 4-indol-3-ylmaselina
061ske27jp ,
unii-061ske27jp
indole 3-butyric acid
FT-0602391
NCGC00164296-03
AM20060321
4-indol-3-ylbutyric acid [hsdb]
4-indol-3-ylbutyric acid [iso]
indolebutyric acid [mi]
S2253
AB00375585-03
3-indole butyric acid
SCHEMBL35884
CG-0518
SCHEMBL1087345
MLS006011821
smr001252209
3-indolebutyricacid
933-32-4
STR04308
3-indolebutyric acid (iba)
chryzosan
chryzopon
4-(3-indolyl)-butyric acid
chryzotek
4-(1h-indol-3-yl)butanoic acid #
4-(indol-3)-butyric acid
4-(3-indole)butyric acid
HMS3604N19
mfcd00005664
SR-01000477768-3
SR-01000477768-1
sr-01000477768
indole-3-butyric acid, pestanal(r), analytical standard
HMS3655J16
indole-3 butyric acid
4-(3-1h-indolyl)butyric acid
indole-3 butyrate
4-(indolyl)- butyric acid
indole-3-butrylic acid
4-(indolyl)- butyrate
4-(3-1h-indolyl)butyrate
4-(3-indole)-butyric acid
4-(indol-3-yl)butyrate
4-indol-3-ylbutyrate
indolebutyrate
b-indolebutyrate
indole-3-butrylate
4-(1h-indol-3-yl)-butyrate
b-indolebutyric acid
indole 3-butyrate
3-indole butyrate
indolyl-3-butyrate
beta-indolebutyrate
3-iodolebutyrate
4-(3-indole)-butyrate
4-(3-indolyl)butyrate
indole-3-butyric acid, vetec(tm) reagent grade, 98%
3-indolebutyric acid, 98%
NCGC00164296-05
Z56754864
SW219851-1
CS-6288
HY-N0186
Q2622539
4-(3-indolyl)butyric acid 100 microg/ml in acetonitrile
4-indol-3-ylbutyric-acid
BCP00909
EN300-16684
SB15075
3-indolebutyric-acid
D78109
NCGC00164296-02

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Growth indexes increased with the increase of the dosage of photohormones before reaching a peak value, and then decreased."( Growth promotion of Yunnan Pine early seedlings in response to foliar application of IAA and IBA.
Cai, N; Li, G; Li, Y; Liu, D; Xu, Y; Zhang, Y; Zhao, M, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
auxinAny of a group of compounds, both naturally occurring and synthetic, that induce cell elongation in plant stems (from Greek alphaupsilonxialphanuomega, "to grow").
plant hormoneA plant growth regulator that modulates the formation of stems, leaves and flowers, as well as the development and ripening of fruit. The term includes endogenous and non-endogenous compounds (e.g. active compounds produced by bacteria on the leaf surface) as well as semi-synthetic and fully synthetic compounds.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
indol-3-yl carboxylic acidAny indolyl carboxylic acid carrying an indol-3-yl or substituted indol-3-yl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
SMAD family member 2Homo sapiens (human)Potency27.53570.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency27.53570.173734.304761.8120AID1346859
AR proteinHomo sapiens (human)Potency23.70820.000221.22318,912.5098AID588515; AID588516; AID743036; AID743053
retinoid X nuclear receptor alphaHomo sapiens (human)Potency44.66840.000817.505159.3239AID588544
estrogen nuclear receptor alphaHomo sapiens (human)Potency15.54740.000229.305416,493.5996AID588514; AID743075
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency19.95260.001024.504861.6448AID588534
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency44.66840.001019.414170.9645AID588536
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency1.94940.023723.228263.5986AID743222
activating transcription factor 6Homo sapiens (human)Potency48.96620.143427.612159.8106AID1159516
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency61.13060.000627.21521,122.0200AID651741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-lactamase class B VIM-2 Pseudomonas aeruginosaIC50 (µMol)757.00001.66004.38678.0000AID1254039
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-lactamase Klebsiella pneumoniaeKd430.00000.85000.85000.8500AID1320842
Beta-lactamase class B VIM-2 Pseudomonas aeruginosaKd274.00000.60000.60000.6000AID1254041
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (50)

Assay IDTitleYearJournalArticle
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1291427Inhibition of His-tagged Klebsiella pneumoniae NDM-1 expressed in Escherichia coli BL21-AI cells using imipinem as substrate2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Fragment-based discovery of inhibitor scaffolds targeting the metallo-β-lactamases NDM-1 and VIM-2.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID439612Antagonist activity at human T1R2/T1R3 receptor expressed in HEK293E cells assessed as inhibition of sucralose-induced intracellular calcium mobilization2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Phenoxy herbicides and fibrates potently inhibit the human chemosensory receptor subunit T1R3.
AID1254038Inhibition of Pseudomonas aeruginosa 301-5473 metallo-beta-lactamase VIM-2 expressed in Escherichia coli BL21(DE3) using nitrocefin as substrate at 500 uM preincubated for 5 mins followed by substrate addition measured every 17 secs for 20 mins by micropl2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Discovery of Novel Inhibitor Scaffolds against the Metallo-β-lactamase VIM-2 by Surface Plasmon Resonance (SPR) Based Fragment Screening.
AID1320843Inhibition of native signal containing Klebsiella pneumoniae OXA-48 using nitrocefin substrate pre-incubated for 5 mins before substrate addition2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.
AID1254039Inhibition of Pseudomonas aeruginosa 301-5473 metallo-beta-lactamase VIM-2 expressed in Escherichia coli BL21(DE3) using nitrocefin as substrate preincubated for 5 mins followed by substrate addition measured every 17 secs for 20 mins by microplate reader2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Discovery of Novel Inhibitor Scaffolds against the Metallo-β-lactamase VIM-2 by Surface Plasmon Resonance (SPR) Based Fragment Screening.
AID1291430Ratio of IC50 for inhibition of His-tagged Klebsiella pneumoniae NDM-1 expressed in Escherichia coli BL21-AI cells using imipinem as substrate to Kd for Binding affinity to His-tagged Klebsiella pneumoniae NDM-1 expressed in Escherichia coli BL21-AI cells2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Fragment-based discovery of inhibitor scaffolds targeting the metallo-β-lactamases NDM-1 and VIM-2.
AID1411781Inhibition of LOX (unknown origin)2018MedChemComm, Feb-01, Volume: 9, Issue:2
Recent development of lipoxygenase inhibitors as anti-inflammatory agents.
AID1291429Inhibition of His-tagged Klebsiella pneumoniae NDM-1 expressed in Escherichia coli BL21-AI cells at 500 uM using imipinem as substrate2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Fragment-based discovery of inhibitor scaffolds targeting the metallo-β-lactamases NDM-1 and VIM-2.
AID1291426Binding affinity to His-tagged Klebsiella pneumoniae NDM-1 expressed in Escherichia coli BL21-AI cells by surface plasmon resonance assay2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Fragment-based discovery of inhibitor scaffolds targeting the metallo-β-lactamases NDM-1 and VIM-2.
AID1254041Binding affinity to Pseudomonas aeruginosa 301-5473 metallo-beta-lactamase VIM-2 expressed in Escherichia coli BL21(DE3) measured for 15 secs by SPR analysis2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Discovery of Novel Inhibitor Scaffolds against the Metallo-β-lactamase VIM-2 by Surface Plasmon Resonance (SPR) Based Fragment Screening.
AID1103715Root formation-promoting activity in Vigna mungo (black gram) cuttings at 1 x 10'-4 M relative to IBA (Rvb = 35 +/- 8%)2008Bioscience, biotechnology, and biochemistry, Aug, Volume: 72, Issue:8
Synthesis and biological activities of 4-trifluoromethylindole-3-acetic acid: a new fluorinated indole auxin.
AID1320842Binding affinity to native signal deficient and TEV cleavage site containing His-tagged Klebsiella pneumoniae OXA-48 expressed in Escherichia coli assessed as dissociation constant by SPR assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (234)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (3.85)18.7374
1990's3 (1.28)18.2507
2000's75 (32.05)29.6817
2010's122 (52.14)24.3611
2020's25 (10.68)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.88 (24.57)
Research Supply Index5.49 (2.92)
Research Growth Index5.59 (4.65)
Search Engine Demand Index93.03 (26.88)
Search Engine Supply Index3.02 (0.95)

This Compound (41.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (2.07%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other237 (97.93%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]